H.C. Wainwright has increased its price target for Structure Therapeutics (GPCR, Financial) from $75 to $80, while maintaining a Buy rating on the stock. The firm highlights the unique structural attributes of aleniglipron, noting that these could lead to distinctive weight-loss results in the ACCESS trials. Additionally, the data regarding orforglipron and danuglipron appears optimistic for the future of aleniglipron.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Structure Therapeutics Inc (GPCR, Financial) is $79.00 with a high estimate of $120.00 and a low estimate of $50.00. The average target implies an upside of 208.96% from the current price of $25.57. More detailed estimate data can be found on the Structure Therapeutics Inc (GPCR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Structure Therapeutics Inc's (GPCR, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.